Standen N B, Quayle J M
Department of Cell Physiology and Pharmacology, University of Leicester, UK.
Acta Physiol Scand. 1998 Dec;164(4):549-57. doi: 10.1046/j.1365-201X.1998.00433.x.
Potassium channels play an essential role in the membrane potential of arterial smooth muscle, and also in regulating contractile tone. Four types of K+ channel have been described in vascular smooth muscle: Voltage-activated K+ channels (Kv) are encoded by the Kv gene family, Ca(2+)-activated K+ channels (BKCa) are encoded by the slo gene, inward rectifiers (KIR) by Kir2.0, and ATP-sensitive K+ channels (KATP) by Kir6.0 and sulphonylurea receptor genes. In smooth muscle, the channel subunit genes reported to be expressed are: Kv1.0, Kv1.2, Kv1.4-1.6, Kv2.1, Kv9.3, Kv beta 1-beta 4, slo alpha and beta, Kir2.1, Kir6.2, and SUR1 and SUR2. Arterial K+ channels are modulated by physiological vasodilators, which increase K+ channel activity, and vasoconstrictors, which decrease it. Several vasodilators acting at receptors linked to cAMP-dependent protein kinase activate KATP channels. These include adenosine, calcitonin gene-related peptide, and beta-adrenoceptor agonists. beta-adrenoceptors can also activate BKCa and Kv channels. Several vasoconstrictors that activate protein kinase C inhibit KATP channels, and inhibition of BKCa and Kv channels through PKC has also been described. Activators of cGMP-dependent protein kinase, in particular NO, activate BKCa channels, and possibly KATP channels. Hypoxia leads to activation of KATP channels, and activation of BKCa channels has also been reported. Hypoxic pulmonary vasoconstriction involves inhibition of Kv channels. Vasodilation to increased external K+ involves KIR channels. Endothelium-derived hyperpolarizing factor activates K+ channels that are not yet clearly defined. Such K+ channel modulations, through their effects on membrane potential and contractile tone, make important contributions to the regulation of blood flow.
钾通道在动脉平滑肌的膜电位以及调节收缩张力方面发挥着重要作用。在血管平滑肌中已描述了四种类型的钾通道:电压门控钾通道(Kv)由Kv基因家族编码,钙激活钾通道(BKCa)由slo基因编码,内向整流钾通道(KIR)由Kir2.0编码,以及ATP敏感性钾通道(KATP)由Kir6.0和磺脲类受体基因编码。在平滑肌中,据报道表达的通道亚基基因有:Kv1.0、Kv1.2、Kv1.4 - 1.6、Kv2.1、Kv9.3、Kvβ1 - β4、sloα和β、Kir2.1、Kir6.2以及SUR1和SUR2。动脉钾通道受到生理性血管舒张剂的调节,血管舒张剂会增加钾通道活性,而血管收缩剂则会降低其活性。几种作用于与环磷酸腺苷(cAMP)依赖性蛋白激酶相关受体的血管舒张剂可激活KATP通道。这些包括腺苷、降钙素基因相关肽和β肾上腺素能受体激动剂。β肾上腺素能受体也可激活BKCa和Kv通道。几种激活蛋白激酶C的血管收缩剂会抑制KATP通道,并且通过蛋白激酶C对BKCa和Kv通道的抑制作用也已有报道。环磷酸鸟苷(cGMP)依赖性蛋白激酶的激活剂,尤其是一氧化氮(NO),可激活BKCa通道,也可能激活KATP通道。缺氧会导致KATP通道激活,并且也有报道称BKCa通道被激活。缺氧性肺血管收缩涉及Kv通道的抑制。对细胞外钾增加的血管舒张作用涉及KIR通道。内皮衍生的超极化因子激活尚未明确界定的钾通道。这种钾通道调节通过其对膜电位和收缩张力的影响,对血流调节做出了重要贡献。